Selank has small human studies. It does not have a modern evidence package.
Selank is a real seven-amino-acid peptide with two Russian-language anxiety studies, a healthy-volunteer brain-imaging experiment, and extensive preclinical work. That record is more meaningful than a seller claim, but it does not prove broad anxiety treatment, cognitive enhancement, no side effects, or the quality of an online product.
There is a human anxiety signal, but the certainty is low.
Two small Russian-language active-comparator studies reported favorable anxiety outcomes. Their public English abstracts leave important questions about allocation, masking, dose, route, attrition, effect size, adverse-event reporting, and whether the studied intervention matches any current finished product.
A separate healthy-volunteer study measured short-term brain connectivity, not durable relief of an anxiety disorder or improved memory and focus. FDA says important human safety information is lacking for Selank acetate and flags potential product-related immunogenicity concerns.
Read the Selank record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
3 core human papers
Two small anxiety studies and one imaging experiment have important reporting limits.
Inspect the human evidenceLow-certainty anxiety signal
The record does not establish broad anxiety treatment, cognitive enhancement, or product equivalence.
Audit the popular claimsNo FDA-approved US product
FDA retains safety concerns and says important human safety information is missing.
Check status and destination routesDated US price boards
The Selank registry search returns two records, but neither tests Selank.
Search-result count and verified intervention count are different fields. This distinction prevents two unrelated neuromodulation studies from becoming invented Selank trials.
Two fuzzy candidate records
ClinicalTrials.gov's intervention search returned two candidate records on July 21, 2026. NCT01747200 studies rhythmic transcranial magnetic stimulation, while NCT05832060 studies tDCS and tRNS electrical brain stimulation.
Repeat the registry search →Zero verified Selank records
Manual inspection of every intervention name in NCT01747200 and NCT05832060 found TMS, tDCS, and tRNS conditions, with no Selank intervention. The verified Selank intervention count is therefore zero for this search snapshot.
Search the verified peptide trial dataset →Inspect the actual intervention field
Registry search systems can use fuzzy matching, stemming, aliases, or full-record text. Always inspect the intervention field and NCT record before counting a search result as a drug trial.
Read the evidence method →Identity, symptoms, imaging, mechanism, safety, and market access answer different questions.
Every claim should preserve the exact peptide, chemical form, finished product, route, population, endpoint, comparator, source language, and destination.
Selank is a seven-amino-acid tuftsin analogue.
PubChem records the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and the TP-7 synonym. Free peptide, acetate, a study intervention, nasal finished product, compounded preparation, and seller-labelled vial are not automatically the same material or exposure.
Two small active-comparator papers are signals, not a modern approval package.
Russian-language abstracts describe 62 patients compared with medazepam and 60 patients compared with phenazepam. They report favorable anxiety findings, but the public abstracts do not supply the complete allocation, masking, route, dose, attrition, adverse-event, protocol, or statistical record needed for a confident benefit-risk conclusion.
A brain-network change is not symptom relief or better cognition.
A 52-participant study measured short-term resting-state functional connectivity after Selank, Semax, or placebo. It did not establish durable improvement in diagnosed anxiety, memory, focus, productivity, sleep, or daily function.
GABA, enkephalin, memory, and immune findings sit upstream of clinical outcomes.
Cell, plasma-enzyme, gene-expression, and animal experiments can generate hypotheses. They do not prove that an online product treats anxiety, works like a benzodiazepine, improves human memory, prevents infection, or has a known long-term safety profile.
Nomination status, approval, formulation quality, and personal safety are separate records.
FDA's current page keeps Selank acetate in a withdrawn-nomination section while retaining concerns about immunogenicity, aggregation, impurities, and missing human safety information. Withdrawal from a nomination category is not FDA approval, a finding of safety, or validation of a finished product.
A listing proves that a seller page exists, not that a medicine is authorized.
Peptide Local can compare dated US 10 mg research listings and link destination regulators. Price, stock, a certificate route, and shipping language do not establish identity, sterility, clinical benefit, prescriber authority, import permission, or legality in every location.
What the Selank record shows, and what the claim still cannot prove.
Each row keeps a real signal beside the missing evidence, instead of replacing uncertainty with marketing confidence.
Selank treats anxiety
Two Russian-language active-comparator studies report favorable anxiety outcomes in 62 and 60 patients.
The public abstracts do not provide a large multicenter placebo-controlled evidence base, complete adverse-event tables, or enough design detail to establish a current general treatment claim.
Selank improves focus and memory
A healthy-volunteer study measured short-term functional connectivity, while rat experiments reported memory-related findings.
Neither record proves durable improvement in validated human memory, attention, learning, productivity, or daily function.
Selank works like a benzodiazepine without the downsides
Comparator studies and preclinical GABA-related findings create a plausible research question.
Mechanistic overlap and active-comparator results do not establish equal efficacy, no sedation, no withdrawal, no dependence, no interactions, or superior long-term safety.
Selank has no side effects
The small anxiety-study abstracts describe tolerability favorably but do not publish a complete event ledger in the abstract.
FDA says important human safety information is lacking and flags potential immunogenicity from aggregation and peptide-related impurities for compounded products.
Selank is antiviral or immune boosting
Laboratory and animal influenza work reported antiviral and immune-expression signals.
That evidence does not establish prevention or treatment of influenza or another infection in humans, and it does not validate an online finished product.
ClinicalTrials.gov lists Selank trials
The current fuzzy intervention search returns two candidate records.
Their intervention fields list TMS or electrical stimulation, not Selank. Search-result count is not verified intervention count.
Selank and Semax are interchangeable
One 52-participant imaging paper studied the two peptides in separate conditions and reported shared and distinct connectivity findings.
They have different sequences, source records, claims, listings, and regulatory facts. The imaging paper did not establish clinical equivalence or a winner.
Four records, from patient outcomes to an ex vivo mechanism.
This is not a vote count. A clinical comparison, healthy-volunteer surrogate endpoint, and plasma-enzyme experiment have different strengths and cannot be pooled into one efficacy claim.
Generalized anxiety disorder and neurasthenia comparison
- Identity
- Selank intervention; exact chemical form not stated in the English abstract
- Design
- Russian-language randomized controlled trial; active comparator medazepam; Hamilton, Zung, CGI, and serum enkephalin measures
- Participants
- 62 total; 30 Selank and 32 medazepam
The abstract reports similar anxiolytic effects and additional antiasthenic or psychostimulant signals. It does not expose the complete protocol, masking, route, dose, attrition, effect-size, or adverse-event table needed to generalize the result.
Phobic-anxiety and somatoform disorder comparison
- Identity
- Selank intervention; exact form and finished-product identity not stated in the English abstract
- Design
- Russian-language comparative clinical trial; active comparator phenazepam; allocation and masking not described in the abstract
- Participants
- 60 total; group sizes not stated in the abstract
The abstract reports anxiety, mild nootropic, quality-of-life, and one-week persistence findings. It does not provide enough public design or event detail to establish a modern benefit-risk estimate or a no-side-effect claim.
Selank, Semax, and placebo resting-state fMRI study
- Identity
- Selank and Semax studied separately; exact forms and finished formulations not stated in the abstract
- Design
- Resting-state functional-connectivity scans before and 5 and 20 minutes after the assigned condition
- Participants
- 52 healthy participants; condition group sizes not stated in the abstract
The paper reports connectivity differences involving the right amygdala and right temporal cortex. It did not measure treatment of an anxiety disorder or durable improvement in cognition or daily function.
Enkephalin-degrading enzyme experiment
- Identity
- Selank applied to human plasma outside a treated participant
- Design
- Biochemical enzyme-inhibition experiment; no clinical treatment group
- Participants
- Human plasma source count not stated in the abstract
The abstract reports dose-dependent inhibition of enkephalin hydrolysis. An ex vivo plasma signal cannot establish anxiety relief, clinical dose-response, brain exposure, comparative efficacy, or human safety.
US research listings are easier to find than decisive clinical evidence.
Availability and price are market observations, not medical validation. The range excludes shipping, coupons, checkout-only discounts, and rows without a confirmed stock signal.
03
Three public US 10 mg research listings met the current comparison rules. Inclusion does not mean approval, recommendation, product authentication, provider certification, or lawful access in every destination.
Open every source row →02
Two carried an in-stock signal when checked. The third displayed a price and document sections without a captured stock label. Stock does not establish composition, concentration, sterility, fulfillment, or suitability for use.
Check source freshness →$34.99-$37.17
The current confirmed-stock range spans 6% from low to high before landed cost. Compare documentation access and source freshness beside price, then verify the exact product and seller.
Compare landed cost →Approval, compounding nomination, and country marketing status are three records.
An administrative list change is not a safety finding, and one country's warning does not answer every other destination.
No FDA-approved Selank product found
The dated exact-name Drugs@FDA review identified no approved Selank drug record. Research listing, prescription, publication, or certificate does not substitute for an approved finished-product record.
Repeat the Drugs@FDA search →Nomination withdrawn, safety concerns retained
FDA says the nominator intended a different bulk substance, but its current page still flags possible immunogenicity from aggregation and peptide impurities and says important human safety information is missing.
Inspect the FDA record →SAHPRA names Selank
SAHPRA specifically includes Selank among illegally marketed unregistered peptide products. That official warning does not authenticate a listing or decide the status of another product, seller, or destination.
Read the SAHPRA notice →Selank status and seller verification depend on the destination and product.
South Africa has a compound-specific public warning. The US has an FDA safety and nomination record but no identified approved drug. Other destinations may require separate medicine, pharmacy, prescriber, import, advertising, and seller checks. An absent compound-specific finding is not proof of approval or legality.
Twelve Selank questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, mental-health care, or a use protocol.
What is Selank?
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. PubChem also records TP-7 and Selanc as synonyms. That molecular identity does not make a seller vial, acetate material, compounded preparation, study intervention, or nasal finished product interchangeable. Each product still needs its own composition, concentration, formulation, source, quality, and regulatory record.
Does Selank work for anxiety?
Two small Russian-language active-comparator studies report favorable anxiety outcomes. One included 62 people, with 30 receiving Selank and 32 medazepam. Another included 60 people and compared Selank with phenazepam. Those signals deserve careful study, but the public English abstracts do not provide the complete masking, allocation, dose, route, attrition, event, and statistical record needed to support a broad current treatment claim.
Is Selank a nootropic?
Nootropic is a claim category, not proof of a clinical benefit. A 52-participant healthy-volunteer study measured short-term resting-state brain connectivity, and animal studies report learning or memory signals. Neither establishes durable improvement in validated human memory, attention, learning, productivity, school or work performance, or daily function. Seller use of the word nootropic adds no independent evidence.
Does Selank improve focus or memory?
The current record does not establish a reliable human focus or memory benefit. The healthy-volunteer paper used a functional-connectivity surrogate rather than a durable cognitive or functional outcome. Memory experiments identified in PubMed were performed in animals. A measured brain-network or animal-behavior change can generate a hypothesis, but it cannot substitute for a replicated human clinical outcome.
What are Selank side effects?
The small anxiety-study abstracts describe tolerability favorably, but they do not expose a complete adverse-event table or establish incidence rates for a current finished product. FDA says it lacks important human safety information for Selank acetate and flags potential immunogenicity related to aggregation and peptide impurities in compounded products. Long-term effects, interaction risks, formulation differences, and product-specific contamination or concentration errors remain unresolved.
Is Selank FDA approved?
No FDA-approved Selank drug record was identified in the dated Drugs@FDA exact-name review. FDA's current compounding safety page discusses Selank acetate, but a bulk-substance nomination or safety listing is not drug approval. An online research listing, clinician mention, prescription, certificate, or foreign-language paper also does not create FDA approval for a US finished product.
Was Selank removed from FDA Category 2?
FDA's current page places Selank acetate in the section for nominations withdrawn after the nominator indicated that a different bulk substance was intended. That administrative history does not mean FDA found Selank safe, effective, approved, or suitable for compounding. The same page retains concerns about aggregation, peptide-related impurities, immunogenicity, and missing human safety information.
Does ClinicalTrials.gov have Selank trials?
The current fuzzy intervention search returned two candidate records, but manual inspection found no Selank intervention in either record. Their intervention fields describe magnetic or electrical brain stimulation. The verified exact intervention count for this dated search is zero. That does not erase human papers indexed in PubMed because a trial registry and a publication database cover different records.
Is Selank legal in the United States?
There is no single yes-or-no answer for every object and activity described as Selank. FDA approval, compounding eligibility, research-material sale, prescription, product claims, import, administration, and state professional rules are different questions. The current record identifies no FDA-approved Selank medicine. Use the exact product, seller, destination, and intended transaction with official federal and state verification routes rather than relying on a generic legality claim.
Is Selank nasal spray the same as research Selank?
No equivalence should be assumed. A study intervention, compounded spray, seller vial, reconstituted material, acetate form, and marketed nasal product can differ in identity, concentration, excipients, device delivery, impurities, microbiological quality, storage, exposure, and labeling. A paper about one intervention cannot authenticate or validate a separate online finished product.
Selank vs Semax: which is better?
The current evidence does not establish a winner. Selank and Semax have different peptide sequences, claimed uses, source records, regulatory facts, and seller listings. One healthy-volunteer imaging paper studied both in separate conditions and reported shared and substance-specific connectivity findings. It did not prove clinical equivalence, superior anxiety relief, better cognition, or comparative long-term safety.
Can I buy Selank online?
Peptide Local records three dated US 10 mg research seller pages so readers can compare list price, stated stock, document access, shipping language, and source freshness. That market observation is not a recommendation, prescription, product authentication, safety finding, or authorization for human use. Verify the exact product category, seller, destination rules, and source evidence before any transaction.
A human paper does not authenticate a product or supply a regimen.
Selank free peptide, Selank acetate, TP-7, a study intervention, compounded preparation, nasal product, seller vial, and combination with Semax can differ in composition, concentration, formulation, device, impurities, exposure, quality, and risk.
This guide does not provide dosing, reconstitution, nasal preparation, injection, cycling, stacking, anxiety treatment, medication replacement, or tapering instructions. Do not delay or replace licensed mental-health care based on a research listing or this educational record.